in morbidity and mortality (Kumanyika and Savage 1985) makes such analyses particularly important in the assessment o f national hypertensioncontrol policies to insure the adequacy o f the policy for blacks. Past analyses (Drizd, Dannenberg, and Engel 1986 ; Joint National Committee on Detection, Evaluation, and Treatment o f High Blood Pressure 1985) have suggested that, in general, the national hypertensioncontrol policies have had as great, if not a greater, positive impact on the black population than on the white population. These analyses appropriately used blood-pressure level as a key indicator o f the impact o f the policy. Other intermediate measures o f the impact o f national hypertension-control policies included the percentage o f hypertensive persons: (1) aware o f their hypertension, (2) taking antihypertensive medications, and (3) having their hypertension under control (i.e., below an agreed-on cut-point). The ultimate measure o f success of hypertension-control policies is the degree o f reduction in hypertensionassociated disease and death. Some evidence (U.S. Public Health Service 1986) points to a similar impact o f the national policy on hypertension-associated disease and death (i.e., stroke and death from heart disease) in the black and white populations. Future policy analyses will increasingly focus on strategies to reduce the risk associated with mild elevations o f blood pressure, partially because o f past successes in reducing the prevalence o f moderate and severe hypertension. The greater heterogeneity o f risk in black and white populations with mild elevations in blood pressure suggests that, for future gains in efficiency and equity in outcome, past approaches for achieving (and assessing) hypertension control will need to be updated. Blood pressure levels alone may no longer be adequate indicators for such purposes. Tarazi (1985) signaled the potential importance o f other factors in hypertension when he stated that the definition o f hypertension solely in terms of arterial pressure levels has obscured the other biologic dimensions of the disease. One biologic dimension o f hypertension that will become increasingly important in future policy analyses is target organ damage secondary to hypertension. The heart, the brain, the kidneys, and blood vessels throughout the body are major target organs in hyper tension. Recently, the use o f sound waves (echocardiography) to identify heart changes (such as increased left-ventricular mass) (see appendix) has allowed early identification o f target organ damage in the heart before damage is apparent elsewhere (Savage et al. 1979a) . There is increasing evidence that such measures may identify individuals at substantially increased risk o f subsequent morbidity and mortality (independent o f other standard risk factors, including blood pressure level) Casale et al. 1986; Levy et al. 1987a ).
Framingham data (Savage et al. 1983; Savage et al. 1987; Levy et al. 1987b) suggest that the echocardiographic left-ventricular mass helps to integrate the overall blood pressure experience. This assessment of target organ damage may reflect the risk associated with the overall blood pressure experience better than two or three blood pressure tests taken on one or two occasions (the usual approach for evaluating blood pressure level and risk). The finding by Hammond et al. (1986) and Dunn et al. (1983) o f greater echocardiographic evidence o f target organ damage in black individuals with mild hypertension-matched by apparent blood pressure level, age, sex, and treatment status to white hypertensive individuals-suggests that analyses o f hypertension control and policy decisions based on blood pressure level alone may not have the same meaning in black and white populations and may lead to faulty conclusions on the relative impact o f efforts to reduce hypertension-associated morbidity and mortality in black and white populations. The future data requirements for both assessing and planning hypertension-control strategies need to be reexamined. This article describes the apparently similar impact o f national policy on hypertension control in the black and white populations as measured by currently available national indicators. The elements o f a type o f mathematical modeling previously applied to hypertensioncontrol policy (cost-effectiveness analysis) are briefly described. The suggestion is made that future strategies would be improved by an updating o f such analyses, with improved data on stratification o f risk in race-specific analyses. Finally, the article briefly describes a mathematical analysis (based on published Framingham data) that predicts that the stratification of risk associated with echocardiographic assessment o f left-ventricular mass as a continuous variable may represent a breakthrough. This stratification o f risk in the population could, along with several other benefits, allow much more precise assessment o f the adequacy o f hypertension control and aid in more efficient targeting o f resources to reduce the continuing excess cardiovascular morbidity and mortality in the black as compared to the white population. Future incorporation of such information into assessments o f national progress and costeffectiveness modeling would be severely limited without population-based data similar to the Framingham data (an almost exclusively white population sample) for the black population. An important step in efficient allocation o f resources to reduce the apparent excessive hypertension-associated morbidity and mortality in the black population is a more accurate and sensitive approach to monitoring o f rarget organ damage associated with hypertension. Data presented here suggest that echocardiographic assessment o f left-ventricular mass may provide a much-improved assessment o f hypertension status. The best data for planning national policy with such profound health and economic implications are national data from representative samples o f the black and white populations, because o f potential differences between and within racial groups in various areas o f the country (Savage et al. 1979b; Gazes et al. 1986; Savage et al. 1987 ).
Profile of Reduction of Heart Disease and Stroke and Control of Hypertension: Magnitude of the Problem and Progress
Cost-effectiveness modeling in hypertension policy analysis is important partly because o f the magnitude o f the problem and its associated morbidity and mortality. Small changes in policy could have enormous impact on public health and health care costs. Despite substantial progress in disease prevention and health promotion, as well as the emergence o f new important public health concerns, heart disease and stroke remain the number-one cause o f death for black and white men and women in the United States. Heart-disease death rates from 1979 to 1981 were 319.4 deaths per 100,000 population for black men, and 274.4 deaths per 100,000 for white men. Heart-disease death rates during this period for black women were 194.4 deaths per 100,000, and for white women were 131.9 deaths per 100,000. Stroke death rates during this period were 76 and 41.2 per 100,000 for black and white men, respectively. Stroke rates during this two-year period were 60.2 and 34.7 for black and white women, respectively (U.S. Department o f Health and Human Services 1985, vol. 4, pt. 1; see also Manton, Patrick, and Johnson 1987) .
Hypertension-associated cardiovascular disease is a major contributor to this mortality. Based on projections made in the early 1980s from national survey data, 58 million Americans are estimated to be at The annual cost o f treating cardiovascular disease in the United States (most o f which is associated with hypertension) has recently been estimated to be 78.6 billion dollars (Stason 1986 ). Harlan (1987) , citing data from the National Medical Care Utilization Survey indicated that hypertension is the most common chronic disease treated in the medical care system. He has indicated that the per capita cost was about $120 per year in 1980. His analyses indicated that if hypertension is complicated by overt evidence o f atherosclerotic disease or associated with other conditions (e.g., renal disease, diabetes, etc.) the per capita costs increased about tenfold. Stason (1986) estimates that nearly eight billion dollars is being spent directly each year on the treatment o f hypertension in the United States. The number o f individuals with elevated blood pressure taking antihypertensive medications has increased rapidly since the modern era o f hypertensive therapy began in the early 1960s.
In one population-based sample o f adult men followed for the past 27 years, zero (black men) and 3 percent (white men) o f the entire sample of black and white men were taking antihypertensive medications in I960, whereas 59 percent (black men) and 4 l percent (white men) of these subjects were taking such medications two and one-half decades later (Gazes et al. 1986 older with definite hypertension were previously diagnosed as hypertensive (Drizd, Dannenberg, and Engel 1986) . This is an extraordinary example o f the apparently successful relative impact o f preventive action in the black compared to the white population. Over three-fourths o f the diagnosed definite hypertensives reported taking antihypertensive medication " always," " often," or " sometimes" (Drizd, Dannenberg, and Engel 1986) . Among hypertensive individuals, the younger groups were less likely than the older age group to be taking medications-40.9 percent for those 18 to 24 years of age versus 85.4 percent o f those 65 to 74 years o f age. Adult women hypertensives were more likely than hypertensive men to be taking antihypertensive medications (79-3 percent versus 68.9 percent, ageadjusted to the combined population) (Drizd, Dannenberg, and Engel 1986) . Among the male hypertensive subjects the percentage taking antihypertensive medications ranged from 37.6 percent for those aged 18 to 24 to 81.8 percent for those aged 65 to 74. For hypertensive women the percentage taking antihypertensive medications ranged from 44 percent for those aged 18 to 24 to 8"/.2 percent for those aged 65 to 74.
Current data suggest that younger hypertensives with the same level o f blood pressure as older hypertensives benefit from treatment with antihypertensive medications as much if not more than the older hypertensives. O f course, older as well as younger hypertensive patients are recommended to have a trial o f nonpharmacological therapy when appropriate (e.g., weight reduction if they are overweight, salt reduction if they are salt sensitive, and reduced alcohol intake). If such non pharmacological therapy is successful in controlling blood pressure after a few weeks, it may suffice. If not, pharmacological therapy is recommended in addition to the continued attempts at nonpharmacological intervention.
Once diagnosed, black hypertensives were as likely as white hy pertensives to be taking antihypertensive medications (72.7 percent versus 75.1 percent, respectively). W om en who were previously di agnosed as hypertensive were more likely to be taking medications than men. This was consistent in race-specific comparisons. Thus, 75.9 percent and 66 percent o f black diagnosed hypertensive women and men, respectively, and 81 percent and 68.8 percent o f white diagnosed hypertensive women and men, respectively, were taking antihypertensive medications. Some 88.9 percent o f black women hypertensives aged 65 to 74 were taking antihypertensive medicationsthe highest rate o f all age/sex groups. Thus, 58 percent o f all black women aged 65 to 74 in the United States were taking antihypertensive medications (Drizd, Dannenberg, and Engel 1986) . The question should be raised as to whether the efforts at nonpharmacologic man agement in black hypertensive patients are as great as in white hy pertensive patients, given the relatively greater prevalence of overweight and possibly salt sensitivity in the black population.
From the early 1960s to the late 1970s the systolic blood pressure declined more in black adults than in white adults. The mean ageadjusted systolic blood pressure declined 4 mm H g in white men, 6 mm Hg in white women, 8 mm H g in black men, and 12 mm H g in black women (Drizd, Dannenberg, and Engel 1986) . During this period the decline in mean systolic blood pressure was greatest in the older individuals. For example, the systolic blood pressure declined 12 mm Hg in white men and women aged 65 to 74 compared to a 1 mm drop in those aged 18 to 24.
Repeated cross-sectional blood pressure surveys in several areasMinnesota (Folsom et al. 1983; Luepker et al. 1984) , Baltimore (Apostolides et al. 1978) , Chicago (Berkson et al. 1980) , Charleston (McClure et al. 1982) , Maryland (Entwisle et al. 1983) , and Connecticut (Freeman et al. 1985) -have consistently shown the improvement in blood pressure control, supporting the earlier findings o f the national surveys (Drizd, Dannenberg, and Engel 1986) . Evidence from physician visits (figure 1) continues to show that 'large segments o f the population are undertaking appropriate measures to control their blood pressure'* (Lenfant and Moskowitz 1983) . From 1982 From to 1985 for high blood pressure increased 52.7 percent while visits for other reasons increased 4 .8 percent (U.S. Public Health Service 1986). The increased visits provide an opportunity for more effective use of nonpharmacological adjunct or primary therapy for elevated blood pressure, which has in some ways lagged behind pharmacological management. For example, the percentage o f adult individuals who are overweight (roughly 40 to 45 percent o f black women and 20 percent of white men, white women, and black men) has not changed from the early 1960s to the late 1970s (Kumanyika and Helitzer 1985) . Nevertheless, the blood-pressure changes are believed to have made an important contribution to the documented decline in mortality from heart disease and stroke since the 1960s. From 1972 to 1984 the death rate from heart disease, in general, fell 33.9 percent (U.S. Public Health Service 1986). From 1980 to 1986 this death rate fell at least another 9 percent. Between 1968 and 1976 the annual ageadjusted coronary-heart-disease death rate in all race/sex groups except white women declined by 60 to 70 per 100,000 ( 2. Some evidence from the mid-1970s suggests that cardiovascular disease mortality may show a decreased rate o f decline in black men and women and white women in contrast to the unchanged rate of decline in white men (Sempos et al. 1986 ).
3. Clinical trial information suggests that the reduction in heart disease deaths associated with reducing blood pressure with medications is less (" fraction o f benefit" equals 40 to 60 percent) than that predicted from observational epidemiologic studies (Russell 1987; Kuller et al. 1986 ). This is in contrast to the fraction o f benefit (nearly 100 percent) in reduction o f stroke. Subgroups o f subjects with resting electro cardiographic abnormalities (including changes suggesting left-ventricular hypertrophy) at baseline who were treated with diuretics had a sig nificantly greater heart disease mortality than those that had no such resting abnormalities or that were less vigorously treated with diuretics (Kuller et al. 1986 ).
Hypertensive patients with some forms o f left-ventricular hy
pertrophy may be made worse when treated with some classes of antihypertensive agents (Topol, Traill, and Fortuin 1985; Savage 1987a ).
Some evidence suggests that black patients may be more likely to have such conditions (Topol, Traill, and Fortuin 1985; Savage 1987b ).
Some classes o f antihypertensive agents (diuretics and beta blockers)
have been associated with modest unwanted changes in blood lipid profiles (W right 1987).
6. New classes o f antihypertensive agents are increasingly being used instead o f diuretics as first-step therapy for hypertension. These agents are substantially more expensive than diuretics (Gallup and Cotugno 1986; Saunders 1986 ).
As noted above, policy changes in hypertensive management should be carefully considered because o f their potentially large health and economic impact. Groundwork for quantitative considerations o f such policy was laid in the m id-1970s by Weinstein and Stason (1976) .
Cost-effectiveness Modeling in Hypertension
In 1976 They took the social perspective and counted all costs, regardless o f who paid them, and all health effects, no matter who experienced them. The cost per year o f life gained was calculated using the following formula: cost per year = net costs/net health effects.
As summarized by Russell (1987) , net costs are the total costs o f treatment, minus the savings in medical costs secondary to heart attacks and strokes prevented, plus the costs o f treating side effects o f the medications, plus ordinary medical costs during the years o f life added by the treatment. The net health effects included years o f life added by drug therapy, plus improvements in health because o f treatment (valued in an equivalent number o f years o f life), minus the side effects o f drugs (also calculated in an equivalent number o f years o f life). As noted, the Framingham data gave the risk o f heart disease, stroke, and death as a function o f blood pressure level. These data fit a logistic curve (i.e., risk o f death or disease rose more rapidly at higher levels o f blood pressure). For example, a ten-point rise in blood pressure from 115 mm H g to 125 mm H g is associated with a greater increment in risk o f disease or death than an increase from 95 mm H g to 105 mm H g (Russell 1987 ). Data were available for white men and women but not for black subjects.
Weinstein and Stason derived their information on effectiveness of treatment from the Veterans Administration clinical trials. Statistical information was not totally adequate for all ages and different lengths o f treatment, so they used expert opinions for filling in such gaps in information not available from the trials. They expressed the benefits o f antihypertensive therapy in terms o f the gain in " quality-adjusted life years." This adjustment allows one to equate a number o f years with poor health (e.g., with side effects o f medicines) that people would give up in order to have a year o f good health (e.g., with no heart disease). They used a number o f simplifying assumptions and used national death rates to estimate the remaining parameters. Thus, they estimated that the cost o f treatment o f hypertension was $4,850 per year o f life gained for people with moderate or severe hypertension (Russell 1987) . This rose to $7,000 if the cost o f screening to identify the individual was included. Age at identification, sex, and initial blood pressure were variables that affected these costs. Adherence to therapy had an important effect since lack o f adherence could increase the cost 30 percent to as much as four-fold more (Russell 1987) . In a recent update, the cost o f screening and treatment for persons with a diastolic pressure o f 105 mm H g was $12,000 per quality-adjusted year o f life gained in 1984 dollars (assuming incomplete adherence) (Stason 1986 ). This increased to more than $60,000 per person per quality-adjusted year o f life gained for those with diastolic blood pressure o f 90-94 mm Hg.
Hypertensive patients with mild elevations o f blood pressure are a heterogeneous group with a lower benefit relative to the cost o f phar macologic treatment. This has increased interest in both nonpharmacologic treatment and in further stratification o f this group into high-and low-risk individuals. This could mean that perhaps millions o f individuals with mild hypertension could be identified as being at such low risk that they need only be managed with nonpharmacologic therapy. A smaller subgroup (that also had apparently mild hypertension on the basis o f their blood pressure level) might be identified who were at much higher risk and might need both pharmacologic and (Casale et al. 1986 ).
Echocardiograms performed in the Framingham study sample will allow the model to be tested directly in a population-based sample o f white adults. As noted earlier, preliminary follow-up data from
Framingham have already shown the echocardiographic left-ventricular mass to be a powerful risk marker for two-year all-cause mortality in men and women from the original cohort, independent o f the standard cardiovascular risk factors . Further analyses will allow more precise coefficients to be developed for the relation o f cardiovascular morbidity and mortality to the level of echocardiographic left-ventricular mass. The utility o f echocardiographic left-ventricular mass as a tool for stratification o f risk will depend partially on the precision o f these coefficients. N o such data are available for blacks. Figure 4 records the distribution o f left-ventricular mass for a general population sample o f Framingham (white) men ) and for a small general population sample o f black men aged 60 to 69 (Gazes et al. 1986 ). The relative shift in left-ventricular mass in black men to higher left-ventricular mass remained after various age-group-and blood-pressure-specific comparisons. 
Echo L V M ass

Conclusions and Implications
These data are o f importance for policy decisions regarding hypertensive patients in general but have particular significance for black hypertensive patients. If the above-cited two-fold greater prevalence o f echocar diographic left-ventricular hypertrophy in blacks with mild hypertension, as compared with white hypertensives, has generality to the nation, the model would suggest significant differences in the meaning of mild hypertension in black and white hypertensives. This would suggest potentially different strategies for reducing hypertension-associated morbidity and mortality in black and white mild hypertensives. This 
Appendix M ath em atical M odel P redictin g the Prognostic Power o f Echocardiographically Determ ined Left-ven tricu lar M ass (figure 2 )
Echocardiography, the use o f sound waves to assess the structure and function o f the heart, is widely accepted as the most sensitive and specific tool widely available for detecting left-ventricular hypertrophyincreased mass or weight o f the left ventricle (Liebson, Devereux, and Horan 1987) . The electrocardiogram (EKG) and the chest x ray were used in the past to assess left-ventricular hypertrophy or heart enlargement associated with hypertension. The EKG is still recommended for assessment o f cardiac target-organ damage as part o f the assessment o f all hypertensive patients. It is a highly specific tool for detection o f left-ventricular hypertrophy but is not very sensitive. Echocardiography maintains the high specificity o f electrocardiography for this diagnosis (Savage etal. 1987 (Savage etal. , 1979a while achieving a high sensitivity (correlations with autopsy left-ventricular mass exceed 0.9) (Devereux and Reichek 1977) . Thus, only about 10 percent o f subjects with echocardiographic left-ventricular hypertrophy are detected by the EKG, while almost all o f the subjects with electrocardiographic left-venticular hypertrophy are detected by the echocardiogram (Savage et al. , 1979a . The chest X ray does even less well than the other two tests (Savage et al. 1979a (Savage et al. , 1983 3. The relation between this continuous measure and disease outcomes can be described by a logistic model.
The assumption that there is a continuous underlying process is reasonable and is supported by most o f the recent literature . The second assumption, that the process has a normal distribution, is made for mathematical simplicity. This assumption is not crucial to the derivation but simplifies the mathematics involved. This as sumption could be varied in future analyses. The third assumption, that the relation between the continuous measure and outcome can be described by a logistic equation, is also made for mathematical convenience but the logistic model is the model most generally used in epidemiology to describe the relation between characteristics associated with risk (" risk factors" ) and outcome variables. In addition, since the model has two parameters, a two-point estimation procedure can be used.
Having assumed a normal distribution for the underlying charac teristic, it was reasoned that the comparison o f the upper 2.5 percent o f the population with the lower 97.5 percent o f the population is approximately equivalent to comparing a person at the mean with a person at the 99th percentile. This assumption was verified by running simulations that indicated that this reasoning was approximately correct, but somewhat conservative. That is, it led to a smaller coefficient than the true one. Nonetheless, this conservative result was used since it was desirable to explore possible relationships and to avoid over estimating the size o f these relationships. As indicated, the logistic function involves two parameters. Knowing the value at two points on the X scale, one can derive estimates o f the unknown parameters.
The simulations involved taking the known relation between a continuous variable, for example diastolic blood pressure, and an outcomecardiovascular death-and generating populations such that blood pressure was normally distributed and such that the probability of cardiovascular death was described by a logistic function. The diastolic blood pressure in the population was then dichotomized at the 99th percentile and the rate o f disease compared in the two groups. The logistic parameters were estimated using the procedure subsequently used for LV mass and these were compared to the known parameters (available from previously published Framingham data, Shurtleff 1974).
The results were reasonably close to the underlying logistic function. The simulations were done for populations o f several sizes, and were repeated several times for each population o f fixed size.
To simplify the problem o f parameter estimation and to focus efforts on exploring the relation between left-ventricular mass and cardiovascular sequelae, all analyses, except one, were restricted to males in a tenyear age group, 45 to 54 years. The same procedure was carried out for total cholesterol for comparison. Finally, using the conservative assumption that electrocardiographic left-ventricular hypertrophy rep resented the 99th percentile o f echocardiographic left-ventricular mass (indexed to body size), the relation o f echocardiographic left-ventricular mass could be plotted between the 99th percentile and the mean risk o f cardiovascular death for men without electrocardiographic left-ventricular hypertrophy using the logistic function. This resulted in the predicted relation between the percentiles o f echocardiographic left-ventricular mass and cardiovascular death shown in figure 2. The relation o f diastolic blood pressure and total cholesterol to cardiovascular death is also shown in figure 2.
